EXACT Sciences Corporation (EXAS) Stock Analysis

EXACT Sciences Corporation (EXAS) is a publicly traded company in the HEALTHCARE sector. It trades at $104.91. This page summarizes the public market data, fundamentals, and frequently asked questions for EXAS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DIAGNOSTICS & RESEARCH

Exchange: NASDAQ

Key Metrics

• Price: $104.91

Market Sentiment

EXACT Sciences Corporation currently has a Bullish sentiment score of 0.16.

About EXACT Sciences Corporation

Exact Sciences Corporation is a pioneering company in cancer diagnostics, dedicated to enhancing early detection and treatment outcomes through its innovative screening and diagnostic tests. Based in Madison, Wisconsin, the firm is best known for its flagship Cologuard test, which significantly advances the early detection of colorectal cancer. With a commitment to transforming cancer care, Exact Sciences harnesses state-of-the-art technology and robust research initiatives to drive growth an...

GNG Research Analysis

GNG Research scores EXACT Sciences Corporation (EXAS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for EXAS.

Frequently Asked Questions

Does EXAS pay dividends?

EXACT Sciences Corporation (EXAS) does not currently pay a regular dividend.